Drug Trial Radar · NCT03556228
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
242
Planned (sponsor's estimate)
Start
Jun 8, 2018
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- VM Oncology, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Conditions
- Head and Neck Carcinoma
- Adenoid Cystic Carcinoma
- Lung Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Mesothelioma
- Esophageal Cancer
- Any Solid Tumors Progressed After a Prior Immunotherapy
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma HNSCC
- Salivary Gland Carcinomas
- Head and Neck Cancers - Salivary Gland
- Head and Neck Cancers - Nasopharyngeal
- Head and Neck Cancers - Throat
- Small Cell Lung Cancer ( SCLC )
- Lung Cancer (Locally Advanced or Metastatic)
- Head and Neck Cancers - Tonsils
- Head and Neck Cancers Hypopharynx
- Head and Neck Cancers Larynx
- Head and Neck Cancers Lip
- Head and Neck Cancers Nasopharynx
- Head and Neck Cancers Oral Cavity
- Head and Neck Cancers
- Head and Neck Cancers Oropharynx
- Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg TabletDrug
Taken orally once daily for 21 days per 21-day cycle
VMD-928 Tablet and Pembrolizumab (200 mg)Drug
VMD-928 tablet (oral) starting at 300 mg daily for 21 days of 21-day cycle. Pemprolizumab at fixed intravenous dose of 200 mg once-every-21 days (per cycle) for max. 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of treatment-emergent Adverse Events (Phase 1)Time frame: First cycle (21 days per cycle)
- To determine the recommended Phase 2 dose for VMD-928 (Phase 1)Time frame: First cycle (21 days per cycle)
- To determine the RP2D of VMD-928 in combination with pembrolizumab (Phase 1)Time frame: First cycle (21 days per cycle)
- Antitumor activity of VMD-928 in subjects with TrkA-driven tumors (Phase 2)Time frame: Up to 18 months
- Antitumor activity of VMD-928 in combination with pembrolizumab in subjects with TrkA-driven tumors (Phase 2)Time frame: Up to 18 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Providence Medical Foundation (site 209)
Santa Rosa, California · Recruiting
Hartford Hospital (site 210)
Hartford, Connecticut · Recruiting
The George Washington University Cancer Center (site 212)
Washington D.C., District of Columbia · Recruiting
Holy Cross Hospital (site 213)
Fort Lauderdale, Florida · Recruiting
Memorial Cancer Institute at Memorial Healthcare Systems (site 132)
Pembroke Pines, Florida · Recruiting
Englewood Hospital and Medical Center (site 202)
Englewood, New Jersey · Recruiting
Summit Medical Group (site 205)
Florham Park, New Jersey · Recruiting
Atlantic Health System, Morristown Medical Center (site 124)
Morristown, New Jersey · Recruiting
Presbyterian Kaseman Hospital (site 208)
Albuquerque, New Mexico · Recruiting
Weill Cornell Medicine, Cornell University (site 126)
New York, New York · Recruiting
Cancer Care Associates of York (site 206)
York, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center (site 127)
Houston, Texas · Recruiting
PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200)
San Juan, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.